Full Press Release Details
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 SHR 4849 , a Potential First in Class DLL3 TOP1 ADC.
IDYA
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 SHR 4849 , a Potential First in Class DLL3 TOP1 ADC
Key Takeaway: IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 SHR 4849 , a Potential First in Class DLL3 TOP1 ADC